Invivyd Shares Give Back Some Gains After Surge From FDA Emergency Approval
By Ben Glickman
Shares of Invivyd eased in after-hours trading Friday, pulling back from regular-session gains on news of emergency approval for its monoclonal antibody treatment.
Shares were down 2.8% to $4.24 in after-hours trading, following a 41% rise at Friday's close. The stock has risen 12% in the last three months.
Invivyd said Friday that the Food and Drug Administration had given emergency-use permission to Pemgarda for preventing Covid-19 in immunocompromised adolescents and adults.
The treatment is administered as an intravenous infusion and is indicated for people 12 and older weighing at least 40 kilograms, or about 88 pounds.
Chief Executive David Hering said the company expected to have product available in the U.S. imminently.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 22, 2024 18:46 ET (22:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?